Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT00003356
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • aldesleukin — BIOLOGICAL
  • rituximab — BIOLOGICAL

Study Details

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining rituximab and interleukin-2 intreating patients who have low-grade mantle cell lymphoma or follicular lymphoma.

Key Dates

Start date
Nov 30, 1997
Status verified
Oct 2013
Primary completion
May 31, 2002
Completion
May 31, 2002

Study Design

Enrollment
58 participants (estimated)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
University of Rochester Cancer CenterRochesterNew York14642-

Find similar trials in Rochester, NY

By research site
University of Rochester Cancer Center· Rochester, NY

Related Studies